Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (241-250 of 466) with videos related to

Pageof 47
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2020
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension StudyMatthew S Davids, Bryone J Kuss, Peter Hillmen, et al.
Leukemia & Lymphoma|October 20, 2021
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trialDominic Kaddu-Mulindwa, Vadim Lesan, Christian Berdel, et al.
Leukemia|November 16, 2019
Elevated Hedgehog activity contributes to attenuated DNA damage responses in aged hematopoietic cellsAnnika Scheffold, Ali H Baig, Zhiyang Chen, et al.
American Journal of Hematology|September 9, 2014
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformationPetra Langerbeins, Raymonde Busch, Nadine Anheier, et al.
British Journal of Haematology|February 19, 2021
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN studyStephan Stilgenbauer, Francesc Bosch, Osman Ilhan, et al.
Hemasphere|July 15, 2021
The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma CellsMoritz Bewarder, Maximilian Kiefer, Helene Will, et al.
Cancers|October 23, 2021
Landscape of 4D Cell Interaction in Hodgkin and Non-Hodgkin LymphomasSylvia Hartmann, Sonja Scharf, Yvonne Steiner, et al.
Leukemia & Lymphoma|September 21, 2018
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenanceNatali Pflug, Paula Cramer, Sandra Robrecht, et al.
Leukemia & Lymphoma|May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study GroupPaula Cramer, Anna-Maria Fink, Raymonde Busch, et al.
Leukemia & Lymphoma|July 9, 2016
Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapyRoxanne C Jewell, Thomas J Kipps, Jan Dürig, et al.
Pageof 47

Showing results (241-250 of 466) with videos related to

Sort By:
Pageof 47
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2020
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension StudyMatthew S Davids, Bryone J Kuss, Peter Hillmen, et al.
Leukemia & Lymphoma|October 20, 2021
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trialDominic Kaddu-Mulindwa, Vadim Lesan, Christian Berdel, et al.
Leukemia|November 16, 2019
Elevated Hedgehog activity contributes to attenuated DNA damage responses in aged hematopoietic cellsAnnika Scheffold, Ali H Baig, Zhiyang Chen, et al.
American Journal of Hematology|September 9, 2014
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformationPetra Langerbeins, Raymonde Busch, Nadine Anheier, et al.
British Journal of Haematology|February 19, 2021
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN studyStephan Stilgenbauer, Francesc Bosch, Osman Ilhan, et al.
Hemasphere|July 15, 2021
The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma CellsMoritz Bewarder, Maximilian Kiefer, Helene Will, et al.
Cancers|October 23, 2021
Landscape of 4D Cell Interaction in Hodgkin and Non-Hodgkin LymphomasSylvia Hartmann, Sonja Scharf, Yvonne Steiner, et al.
Leukemia & Lymphoma|September 21, 2018
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenanceNatali Pflug, Paula Cramer, Sandra Robrecht, et al.
Leukemia & Lymphoma|May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study GroupPaula Cramer, Anna-Maria Fink, Raymonde Busch, et al.
Leukemia & Lymphoma|July 9, 2016
Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapyRoxanne C Jewell, Thomas J Kipps, Jan Dürig, et al.
Pageof 47